Table 1.
Patient characteristics by grade of MTX adherence divided by MMAS-8 (n = 165)
| All (n = 165) |
MMAS-8 | p value | |||
|---|---|---|---|---|---|
| Low (n = 20) |
Medium (n = 99) |
High (n = 46) |
|||
| Age, median (IQR) |
64 (54–72) |
58 (44–62) |
65 (53–73) |
65.5 (59–74) |
0.01 |
| Female, n (%) | 142 (86.1) | 18 (90.0) | 84 (84.6) | 38 (82.6) | 0.74 |
| MTX dose (mg/week), median (IQR) | 8 (6–12) | 10 (8–12) | 8 (6–10) | 10 (8–12) | 0.17 |
| MTX dosing frequency (times/week), median (IQR) | 3 (2–3) | 3 (2–3) | 2 (2–3) | 2 (2–3) | 0.54 |
|
Duration of MTX treatment (month), median (IQR) |
36 (17–75) | 32 (16–79) | 35 (18–80) | 41 (13–74) | 0.15 |
|
Disease duration (month), median (IQR) |
53.5 (22.5–123.5) |
35 (22–120) |
47 (22–111) |
60.5 (24–158) |
0.95 |
| Concomitant medication | |||||
| NSAIDS, n (%) | 59 (35.8) | 5 (25.0) | 36 (36.4) | 8 (39.1) | 0.53 |
| Corticosteroid, n (%) | 27 (16.4) | 2 (10.0) | 17 (17.2) | 8 (17.4) | 0.71 |
| Biologics, n (%) | 48 (29.1) | 7 (35.0) | 28 (28.3) | 13 (28.3) | 0.83 |
| DAS28-ESR, median (IQR) |
2.30 (1.68–3.00) |
2.01 (1.37–2.23) |
2.32 (1.68–3.02) |
2.40 (2.01–3.15) |
0.08 |
| mHAQ, median (IQR) |
0 (0–0.13) |
0 (0–0.25) |
0 (0–0) |
0.13 (0–0.38) |
0.02 |
| BMQ necessity-concern differential, median (IQR) | 1 (0–3) | 2 (0–3) | 1 (0–3) | 2 (0–3) | 0.81 |
| CES-D (total score ≥ 16), n (%) | 37 (26.4) | 8 (47.1) | 21 (8.3) | 8 (20.0) | 0.10 |
| BPI (average NRS pain score), median (IQR) | 2 (1–3) | 1 (1–4) | 1 (1–3) | 1 (3–4) | 0.13 |
| SDS, median (IQR) | 6 (4–7) | 4 (3–6) | 6 (4–6) | 6.5 (5–8) | 0.00 |
| SF-8 (PCS), median (IQR) |
48.1 (42.4–52.1) |
47.4 (45.8–52.1) |
49.8 (43.5–52.1) |
45.6 (40.2–50.2) |
0.04 |
| SF-8 (MCS), median (IQR) |
50.2 (45.6–54.1) |
47.7 (43.0–53.2) |
50.3 (46.3–53.9) |
50.0 (46.1–55.0) |
0.36 |
| Marital status (married), n (%) | 95 (57.9) | 11 (55.0) | 61 (62.2) | 23 (50.0) | 0.37 |
| Educational level (greater than or equal to college level), n (%) | 36 (21.8) | 5 (25.0) | 17 (17.2) | 14 (30.4) | 0.19 |
| Employment status (full-time), n (%) | 38 (23.0) | 12 (60.0) | 22 (22.2) | 4 (8.7) | 0.00 |
| Living status (living alone), n (%) | 43 (26.4) | 7 (35.0) | 24 (24.5) | 12 (26.7) | 0.62 |
IQR interquartile range; DAS28-ESR Disease Activity Score (28 joint count)- erythrocyte sedimentation rate; mHAQ modified Health Assessment Questionnaire; BMQ Beliefs about Medicines Questionnaire; CES-D Center for Epidemiological Studies Depression; BPI Brief Pain Inventory; NRS Numerical Rating Scale; SDS Social Desirability Scale; SF-8 8-item Short-Form Health Survey; PCS physical component summary; MCS mental component summary; MTX methotrexate; MMAS-8 Morisky Medication Adherence Scale